Navigation Links
XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

VALLEY COTTAGE, N.Y., Feb. 7 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the 10th Annual BIO CEO & Investor Conference. Mr. Bentsur will present an overview of the Company including a discussion of Bicifadine, the Company's late-stage clinical compound for the treatment of diabetic neuropathic pain. Mr. Bentsur's presentation will take place on Wednesday, February 13, 2008 at 1:15 pm EST at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation will be available at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=XTL&item_id=175250 2. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD. XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of therapeutics for the treatment of neuropathic pain and HCV. XTL is developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL is also developing novel pre-clinical HCV small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ and Tel-Aviv Stock Exchanges (Nasdaq: XTLB; TASE: XTL).


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
2. Nabi Biopharmaceuticals to Present at the BMO Capital Markets Focus on Healthcare Conference
3. China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results
4. Nabi Biopharmaceuticals Stockholders Approve Asset Sale
5. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
6. RiskMetrics Group (ISS) and Glass Lewis & Co. Support Nabi Biopharmaceuticals Proposed Asset Sale
7. XTL Biopharmaceuticals to Present at the Rodman & Renshaw 9th Annual Health Care Conference
8. XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
(Date:5/20/2016)... (PRWEB) , ... May 20, 2016 , ... Korean researchers ... that it may offer a new way to treat the disease. Surviving Mesothelioma has ... now. , Scientists from several Korean institutions based their mesothelioma study on the ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):